mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
- PMID: 11566616
- DOI: 10.1677/erc.0.0080249
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
Abstract
The mammalian target of rapamycin (mTOR) is a central regulator of G1 cell cycle protein synthesis that precedes commitment to normal cellular replication. We have studied the effect of cell cycle inhibitor-779 (CCI-779), a rapamycin ester that inhibits mTOR function, on the proliferation of a panel of breast cancer cell lines. Six of eight lines studied were sensitive (IC(50)< or = 50 nM) and two lines were resistant (IC(50)>1.0 microM) to CCI-779. Sensitive lines were estrogen dependent (MCF-7, BT-474, T-47D), or lacked expression of the tumor suppressor PTEN (MDA-MB-468, BT-549), and/or overexpressed the Her-2/neu oncogene (SKBR-3, BT-474). Resistant lines (MDA-MB-435, MDA-MB-231) shared none of these properties. CCI-779 (50 nM) inhibited mTOR function in both a sensitive and a resistant line. In nu/nu mouse xenografts, CCI-779 inhibited growth of MDA-MB-468 (sensitive) but not MDA-MB-435 resistant tumors. Treatment of sensitive lines with CCI-779 resulted in a decrease in D-type cyclin and c-myc levels and an increase in p27(kip-1) levels. There was good correlation between activation of the Akt pathway and sensitivity to CCI-779. Amplification of mTOR-regulated p70S6 kinase, which is downstream of Akt, may also have conferred CCI-779 sensitivity to MCF-7 cells. Taken together, the data suggest that mTOR may be a good target for breast cancer therapy, especially in tumors with Akt activation resulting from either growth factor dependency or loss of PTEN function.
Similar articles
-
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.Clin Cancer Res. 2004 Dec 1;10(23):8059-67. doi: 10.1158/1078-0432.CCR-04-0035. Clin Cancer Res. 2004. PMID: 15585641
-
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.Cancer Res. 2002 Sep 1;62(17):5027-34. Cancer Res. 2002. PMID: 12208757
-
The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.Breast Cancer Res Treat. 2012 Jan;131(2):425-36. doi: 10.1007/s10549-011-1420-7. Epub 2011 Mar 11. Breast Cancer Res Treat. 2012. PMID: 21394501
-
Mammalian target of rapamycin: a new molecular target for breast cancer.Clin Breast Cancer. 2003 Jun;4(2):126-37. doi: 10.3816/cbc.2003.n.018. Clin Breast Cancer. 2003. PMID: 12864941 Review.
-
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.Breast Cancer Res. 2004;6(5):219-24. doi: 10.1186/bcr927. Epub 2004 Aug 12. Breast Cancer Res. 2004. PMID: 15318929 Free PMC article. Review.
Cited by
-
Differentiating mTOR inhibitors in renal cell carcinoma.Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Cancer Treat Rev. 2013. PMID: 23433636 Free PMC article. Review.
-
The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer.Hum Cell. 2020 Oct;33(4):1229-1239. doi: 10.1007/s13577-020-00422-x. Epub 2020 Sep 3. Hum Cell. 2020. PMID: 32880825
-
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.Curr Oncol. 2009 Aug;16(4):25-35. doi: 10.3747/co.v16i4.469. Curr Oncol. 2009. PMID: 19672422 Free PMC article.
-
Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.Curr Oncol. 2022 Jun 1;29(6):4020-4033. doi: 10.3390/curroncol29060321. Curr Oncol. 2022. PMID: 35735430 Free PMC article.
-
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.Invest New Drugs. 2010 Jun;28(3):334-42. doi: 10.1007/s10637-009-9257-1. Epub 2009 May 5. Invest New Drugs. 2010. PMID: 19415181 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous